title: [Helicobacter pylori eradication for gastric MALT lymphoma].
abstract: Clinical features and efficacy of Helicobacter pylori (H. pylori) eradication for patients with gastric MALT lymphoma are reviewed. Gastric MALT lymphoma comprises 1-5% of all gastric malignancies, while 40-50% of primary gastric lymphomas. In approximately 90% of cases, H. pylori infection plays the causative role in the pathogenesis, and H. pylori eradication is nowadays the first-line treatment for this disease, which leads to complete disease remission in 60-90% of cases. Predictive factors for resistance to eradication therapy include absence of H. pylori infection, deep invasion in the gastric wall, t(11:18)/API2-MALT1, and etc. Recently a large-scale Japanese multicenter study demonstrated that the long-term clinical outcome of gastric MALT lymphoma after H. pylori eradication is excellent.
authors: Center for Advanced Medical Innovation, Kyushu University.
authors: Shotaro
authors: S
authors: Nakamura
authors: Takayuki
authors: T
authors: Matsumoto
authors: Takanari
authors: T
authors: Kitazono
mesh_terms: D060740:Disease Eradication / Q000379:methods; D016481:Helicobacter Infections / Q000150:complications / Q000517:prevention & control*; D016480:Helicobacter pylori; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology; D011379:Prognosis; D013274:Stomach Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology